Lonafarnib

Lonafarnib is an oral farnesyltransferase inhibitor used to treat a rare genetic disorder known as Hutchinson-Gilford Progeria Syndrome (HGPS). It works by inhibiting farnesyltransferase, an enzyme involved in the production of progerin, the abnormal protein that accumulates in HGPS patients and affects their cells' ability to divide and grow normally. Lonafarnib helps reduce progerin accumulation and can slow the progression of HGPS. In clinical studies, treatment with lonafarnib resulted in improved physical appearance, increased bone density, and other positive outcomes for patients.

Lonafarnib is a medication that falls under the category of antiprotozoal agents, used for specific parasitic infections. Here's a breakdown of its key characteristics:

• Conditions treated: Lonafarnib is currently approved for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) in children.
• About HGPS: HGPS is an extremely rare genetic disease that causes a rapid aging process in children. It's caused by a mutation in the LMNA gene, leading to abnormal protein production that disrupts cell function.
• How it works: The exact mechanism of how lonafarnib works in HGPS is still under investigation. However, it's believed to target a protein called farnesyltransferase, which plays a role in the abnormal protein processing observed in HGPS. By inhibiting farnesyltransferase, lonafarnib may help improve cell function and potentially slow down the progression of the disease.
• Dosage and form: Lonafarnib comes in capsule form, and the dosage is determined by a doctor based on the child's weight and response to treatment. It's typically taken twice daily with food.
• Benefits: While not a cure, lonafarnib has shown promise in clinical trials to improve some aspects of HGPS, such as delaying bone aging and improving cardiovascular health in children with this condition.
• Side effects: Lonafarnib can cause some side effects, including:
  • Nausea, vomiting, diarrhea
  • Headache
  • Fatigue
  • Muscle pain
  • Abnormal liver function tests (usually mild and monitored by your doctor)
• Important considerations:
  • Lonafarnib is only approved for use in children with HGPS and is not a medication for other conditions.
  • It may not be suitable for everyone, especially those with certain medical conditions or allergies to any ingredients in the medication.
  • Lonafarnib can interact with other medications, so it's important to disclose all medications your child takes to their doctor.
  • Regular monitoring of blood tests and potential side effects is necessary while taking lonafarnib.